Thomas Gad | Founder, Interim CEO & President |
Sue Smith | SVP & Chief Commercial Officer |
Bo Kruse | EVP, Secretary, Treasurer & CFO |
Alec Stranahan | Bank of America Merrill Lynch |
Etzer Darout | BMO Capital Markets |
William Maughan | Canaccord Genuity |
Edouard Mullarky | Guggenheim Securities |
Tessa Romero | JPMorgan Chase & Co. |
Sebastiaan van der Schoot | Kempen & Co. |
Joseph Thome | Cowen |
Good afternoon, and welcome to the Y-mAbs Therapeutics, Inc. Earnings Conference Call for the Third Quarter of 2022. [Operator Instructions].
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans, current and future clinical and preclinical studies in our research and development programs; expectations related to the timing of the initiation and completion of the regulatory submissions, regulatory marketing and reimbursement approvals, including statements with respect to the potential FDA approval and utility of omburtamab pipeline development programs, potential for DANYELZA territory expansion and advancement of SADA, collaborations or strategic partnerships and the potential benefits thereof; expectations related to our anticipated cash runway and the sufficiency of our cash resources.